Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19

BACKGROUND: Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. METHODS: 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:medRxiv
Hoofdauteurs: Ganesh, Ravindra, Pawlowski, Colin, O’Horo, John C., Arndt, Lori L., Arndt, Richard, Bell, Sarah J., Bierle, Dennis M., Borgen, Molly Destro, Hanson, Sara N., Heyliger, Alexander, Larsen, Jennifer J., Lenehan, Patrick, Orenstein, Robert, Puranik, Arjun, Speicher, Leigh L., Tulledge-Scheitel, Sidna M., Venkatakrishnan, AJ, Wilker, Caroline G., Badley, Andrew D., Razonable, Raymund R.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Cold Spring Harbor Laboratory 2021
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8168391/
https://ncbi.nlm.nih.gov/pubmed/34075387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.05.23.21257670
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items